Hims & Hers Health Stock (HIMS) Opinions on FDA Peptide Decisions
FDA Peptide Ruling: Recent regulatory developments have dominated conversations around Hims & Hers Health, with an FDA advisory committee vote…
30,083$
7,10%
Echtzeit-Aktienkurs Hims & Hers Health Inc.
Bid:
Ask:
Nachrichten zur Hims & Hers Health Inc. Aktie
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four…
Hims & Hers Health (HIMS) Draws FDA Peptide Focus, Is The Stock Undervalued?
The latest FDA advisory panel vote on broader peptide compounding access, including BPC-157 and related compounds, has pushed Hims &…
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The…
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder
Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the…
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder
Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the…
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% Run
Hims & Hers Health stock has delivered a very large 5 year gain, yet the latest valuation work suggests the…
HIMS Maintains by Truist Securities -- Price Target Raised to $27
Hims & Hers Health Inc (HIMS) Analyst Rating Update On July 24, 2026, Truist Securities announced it…
Hims & Hers Health (HIMS) Shares Fall After FDA Panels Negative Vote on Emideltide
On July 24, 2026, Hims & Hers Health (HIMS) experienced a decline of over 11% following an unfavorable decision from…
Hims & Hers down as FDA advisors snub first peptide
Hims & Hers (HIMS) stock slides after an FDA advisory panel for the first time in a two-day meeting declines…
HIMS Stock Falls Over 10% Amid Market Fluctuations
On July 24, 2026, Hims & Hers Health Inc (HIMS) experienced a notable decline in its stock price, dropping by…
Hims & Hers Health Slides as Traders Fade Peptide Rally
Hims & Hers Health, Inc. (HIMS) is down 10.4% today. Here is some analysis on what might have caused this…
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes Buy Case (Upgrade)
Hims & Hers stock is upgraded to "Buy" given its upside potential. Heres what investors need to know.…
Hims & Hers falls -10.3%
Hims & Hers (HIMS) is down -10.3%, or -$3.38 to $29.36. Published first on TheFly – the ultimate source for…
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured…
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured…
Hims & Hers – Ich traue einer 8-zu-6-Mehrheit keine 2,2 Mrd. USD zu!
Ich halte die Euphorie um Hims & Hers für verfrüht. Acht Ja-Stimmen gegen sechs Nein-Stimmen bei einer Enthaltung – mit…
Hims & Hers – Der US-Telemedizinanbieter reitet auf einer knappen FDA-Empfehlung!
Eine 8-zu-6-Empfehlung ist keine Zulassung. Die FDA-Berater öffnen Peptide wie BPC-157 für die Apothekenherstellung, doch die Behörde muss erst ein…
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the…
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight - Hims & Hers Health (NYSE:HI
Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to…
Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable
Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²…
Telehealth firms urge FDA to legalize peptides, with guardrails
Telehealth companies including Hims & Hers Health Inc. and Noom Inc. urged a panel of experts to recommend legalizing several…
Does FDA Peptide Shift and CAO Exit Reframe the Bull Case for Hims & Hers Health (HIMS)?
Earlier in July 2026, Hims & Hers Health announced that Chief Accounting Officer and Principal Accounting Officer Irene Becklund will…
FDA Peptide Shift And Leadership Change Could Be A Game Changer For Hims & Hers Health (HIMS)
In July 2026, an FDA advisory committee recommended easing compounding restrictions on several peptides, including BPC-157, while Hims & Hers…
Hims & Hers Health upgraded to Buy on strong operational focus and growth plans despite sector challenges
Hims & Hers Health has been upgraded from Hold to Buy due to its disciplined operations and strategic growth in…
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide?
Hims & Hers Health (HIMS) is back in focus after an FDA advisory panel recommended allowing broader compounding of peptide…
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.4% Rally? GF Value Says Undervalued
On July 23, 2026, Hims & Hers Health Inc (HIMS) shares rose 3.4% today, closing at $32.74. The stock has…
Hims and Hers stock gains on peptide compounding vote outlook
Hims and Hers stock gains on peptide compounding vote outlook…
Hims and Hers stock gains on peptide compounding vote outlook
Hims and Hers stock gains on peptide compounding vote outlook…
HIMS Maintained by Citigroup -- Price Target Raised to $35.00
Hims & Hers Health Analyst Rating Update On July 23, 2026, Citigroup maintained a Neutral rating on…
Why is Hims & Hers Health stock rallying today?
Why is Hims & Hers Health stock rallying today?…